 | Up a level |
Rothschild, Sacha I; Zippelius, Alfred; Eboulet, Eric I; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Ochsenbein, Adrian F; Janthur, Wolf-Dieter; Waibel, Christine; Mach, Nicolas; ... (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of clinical oncology, 39(26), pp. 2872-2880. American Society of Clinical Oncology 10.1200/JCO.21.00276
Froesch, Patrizia; Mark, Michael; Rothschild, Sacha I; Li, Qiyu; Godar, Gilles; Rusterholz, Corinne; Oppliger Leibundgut, Elisabeth; Schmid, Sabine; Colombo, Ilaria; Metaxas, Yannis; König, David; Sessa, Cristiana; Gautschi, Oliver; Früh, Martin (2021). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung cancer, 156, pp. 91-99. Elsevier 10.1016/j.lungcan.2021.04.002
